A Kv1.3 channel-specific blocker alleviates neurological impairment through inhibiting T-cell activation in experimental autoimmune encephalomyelitis.

CONCLUSION: ImK prevents neurological damage by suppressing T-cell activation, suggesting the applicability of this peptide in MS therapy. PMID: 29577640 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/29577640?dopt=Abstract

Source: CNS Neuroscience and Therapeutics - March 25, 2018 Category: Neuroscience Authors: Yuan XL, Zhao YP, Huang J, Liu JC, Mao WQ, Yin J, Peng BW, Liu WH, Han S, He XH Tags: CNS Neurosci Ther Source Type: research